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ABSTRACT  
Objective: The objective of the study is to explore polysaccharide mucilages of Colocasia esculenta (CE), and Fenugreek (FG) as buoyancy enhancing 
agents, and mucoadhesive agents by developing gastroretentive floating tablets of Glipizide.  
Methods: Glipizide loaded floating tablets were developed with CE, and FG alone and in combination of Guar gum (GG), and Hydroxypropyl 
methylcellulose (HPMC) K4M using direct compression technique. The developed formulations have been subjected to evaluation of in vitro 
buoyancy study, in vitro drug release study (pH 1.2), and in vitro bioadhesiveness study. Therefore, the final optimized formulation was subjected to 
Fourier Transform Infrared Spectroscopy (FTIR), Differential scanning calorimetry (DSC), and X-ray powder diffraction (XRD) study. 
Results: The results of the buoyancy study for formulation F1, F2, and F5 revealed that the instant floating lag time, floating time duration of 1 h, 
and exhibited 100% drug release in 4 h. Therefore, the formulations developed with GG (F3), and HPMC K4M (F4) have been exhibited slow floating 
lag time, prolonged floating duration and drug released up to 100 % in 12 h, while; formulations F6, F7, F8, and F9 have been exhibited shortest 
floating lag time, longest floating time duration, the best drug released up to 12 h, and better in vitro bioadhesiveness properties. Furthermore, F7 
exhibited good bioadhesive property as compared to F6, F8-F9. The results of the FTIR, DSC, and XRD study for F7 revealed that the presence of 
functional groups and amorphous. 
Conclusion: Owing to the anticipated properties like biocompatibility, biodegradability, swelling ability, and cost-effectiveness of CE; it could be the 
potential macromolecule for the replacement of synthetic polymers.  
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INTRODUCTION 
Natural powdered extracts are acquired from vegetable sources 
with high molecular weight uronic acid and sugar units [1]. They are 
novel hydrocolloids with a broad range of applications in the 
pharmaceutical era, such as emulsifying agents, gelling agents, 
suspending agents, thickening agents, binders, matrix-forming 
agents, disintegrants, and mucoadhesive agents [2-9]. At present 
numerous scientists have explored natural mucilages in the 
development of novel drug delivery systems. For instance, Reddy et 
al. 2010, developed sustained release matrix tablets of Diltiazem 
using Gum karaya and Gum kondagogu [10], Prajapati et al. 2014 
developed sustained release mucoadhesive macromolecule of 
aceclofenac using Locust bean gum [11], Dwivedi et al. 2017 
prepared sustained release matrix-tablets of metformin with Cassia 
tora mucilage [12], Hadad et al. 2018 developed electrospun-
nanofibers using flax seed mucilage [13], Liang et al. 2015, prepared 
gastric floating controlled-release tablets using Konjac Glucomannan 
[14], Rimi et al. 2005 prepared nasal drug delivery systems of 
diazepam using Trigonella Foenum Graecum [15], Maithi et al. 2010 
developed hydrogel beads of Glipizide using Locust bean gumand 
floating microparticles of metformin using glycinemax [16], 
metroxylonsagu and Plantagoovate by Pandey et al. 2016 [17]. 
Gastroretentive drug delivery system (GRDDS) can prolong the 
retention of drugs in the gastrointestinal region for several hours 
and increase the sustained release of drugs, those which are having 
an absorption window in a particular region of GIT after oral 
administration [18]. The enhanced gastric retention improves 
bioavailability, and increases the solubility of drugs due to its 
extensive advantages [19]. Presently, numerous types of approaches 
have been reported for development of GRDDS which include; 
floating systems, bioadhesive systems, hydrodynamically balanced 
systems, swelling, and expanding systems to enhance the gastric 
residence time [20, 21]. However, these dosage forms are very 
effective, when the fluid level in the stomach is sufficiently high. 
Though, the buoyancy of the tablet may be hindered at pylorus in 
empty conditions [22]. Owing to this, it can be restrained by 
developing the formulation and it may be required to attach the 
mucous membrane of the stomach wall. 
Mucoadhesionhave has been employed for targeted drug delivery by 
the addition of mucoadhesive polymers with active pharmaceutical 
ingredients for the development of pharmaceutical formulations. 
Mucoadhesive materials are hydrophilic macromolecules containing 
assorted hydrogen bond forming groups [23]. CE, and FG powdered 
extracts were previously explored as versatile pharmaceutical 
excipients [15]. These are hydrophilic, biodegradable, 
biocompatible, nontoxic, amusing resources, and have been widely 
employed as additives in the development of drug delivery systems 
[24, 25]. Glipizide is an oral hypoglycemic agent, which is generally 
prescribed drug for the prevention of non-insulin-dependent 
diabetes mellitus (NIDDM) [26], through exciting insulin secretion 
from the pancreatic islets of Langerhans and several other extra 
pancreatic effects, such as enhancing sensitivity to insulin and 
decreasing the hepatic glucose production [27]. Owing to the short 
biological half-life (3.4±0.7 h) of Glipizide, it is administered 2 or 3 
times with doses of 2.5–10 mg per day. It is practically insoluble in 
water and highly permeable (Biopharmaceutical Classification 
System, Class II). Moreover, Glipizide is mostly absorbed from the 
upper parts of the gastrointestinal tract. The dosage forms with 
bioadhesive, and floating properties can sustain the drug release and 
increases the buoyancy of the tablet in the stomach as well as 
improves the oral bioavailability of Glipizide [28-30]. 
In the present study, naturally conquering CE and FG mucilage 
powders have been extracted and used as the Mucoadhesive, and the 
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buoyancy promoting agents in Glipizide-loaded floating tablets 
preparation [31]. The main objective of the present study is to 
develop mucoadhesive, swellable, floating GRDDS by using CE, FG, 
GG, and HPMC K4M alone and in combination to improve gastric 
retention by lowering the floating lag time, and enhancing the 
floating duration with sustained drug release profiles and 
mucoadhesive property of Glipizide loaded GRDDS. Glipizide loaded 
floating tablets optimized based on buoyancy properties, in vitro 
drug release studies, and in vitro mucoadhesive studies.  
MATERIALS AND METHODS  
Materials 
Glipizide was purchased from Yarrow Chemicals Private Limited, 
Mumbai, India. HPMC K4M®, GG, Sodium bicarbonate, Citric acid, 
Magnesium stearate®, Talc (Purified), and Microcrystalline Cellulose 
(MCC®
Methods 
) were purchased from Qualikems Fine Chem Pvt. Ltd. 
Vadodara, Gujarat, India. CE and FG were purchased from the local 
market, Narsampet, Warangal, India. All other purified chemicals 
and solvents were of analytical grade. 
Preparation of Glipizide loaded floating tablets by direct 
compression technique 
Glipizide-loaded floating tablets prepared by using CE, FG, GG, and 
HPMC K4M ®solitary and in combination. These polymers form a 
gel-like matrix after contact with the gastrointestinal fluid to attain 
the low density of formulation as compared to that of GI Fluid (GI 
fluid density ~1)[32]. Citric acid and Sodium bicarbonate were used 
as effervescent agents to produce carbon dioxide and preserve the 
buoyancy of a tablet [32]. Talc, and MCC® were used as glidant, and 
diluent respectively. All the above powders except Magnesium 
stearate® were sieved through a sieve of mesh No# 60. The 
components of the formulations mixed in a cubic mixer for 15 min. 
Magnesium stearate®
 
 was added into the formulation blend a 
lubricant, and mixed for another 5 min. Followed by the blend was 
subjected to tablet preparation by direct compression technique 
(Karnavati double rotary tablet press) [33]. The developed 100 mg 
tablets contained 10 mg of Glipizide. Formulation of Glipizide loaded 
sustained release mucoadhesive floating tablets revealed in table 1. 
Table 1: Formulation of glipizide loaded mucoadhesive sustained release floating tablets: formulations from F1-F9 
S. No. Ingredients (mg) F1 F2 F3 F4  F5  F6  F7  F8  F9 
1 Glipizide 10 10 10 10 10 10 10 10 10 
2 CE 40 -- -- -- 20 20 20 -- -- 
 3 FG -- 40 -- -- 20 -- -- 20 20 
4 GG -- -- 40 -- -- 20 -- 20 -- 
5 HPMC K4M -- -- -- 40 -- -- 20 -- 20 
6 Citric acid 10 10 10 10 10 10 10 10 10 
7 NaHCO 10 3 10  10  10  10 10 10 10 10 
8 MCC 25 25 25 25 25 25 25 25 25 
9 Talc 02 02 02 02 02 02 02 02 02 
10 Magnesium Stearate  03 03 03 03 03 03  03 03 03 
Total weight of tablet (mg) 100 100 100 100 100 100 100  100 100 
GG: Guar Gum; CE: Colocasia esculenta; FG: Fenugreek; HPMC: Hydroxy propyl methylcellulose; MCC: Microcrystalline Cellulose; NaHCO3: Sodium 
bicarbonate. 
 
Evaluation of post-compression parameters  
Glipizide loaded sustained release mucoadhesive floating tablets 
have been subjected to evaluate the thickness, weight variation, 
hardness, friability, and drug content uniformity [34].  
Weight variation test 
The weight variation test has been performed by selecting 20 tablets 
randomly from each formulation and weighed using Mettler Toledo 
Electronic Balance (0.1 mg) (Mettler Toledo India Private Limited, 
Mumbai, India). The results were calculated and reported as mean 
average weight±standard deviation (SD).  
Thickness test 
The thickness of the tablets performed by selecting 10 tablets 
randomly from each formulation and it was the thickness of the 
tablet was measured by using digital Vernier Caliper. The results 
reported as mean thickness±SD.  
Hardness test 
To study the hardness test of Glipizide loaded floating tablets, 6 
tablets from each formulation have been selected and the tablet 
breaking force was recorded using Monsanto hardness tester. The 
hardness results reported as mean±SD. 
Friability study 
20 pre-weighed tablets from each formulation have been selected 
and transferred into Roche friabilator plastic chamber. Then the 
friabilator has been operated at 25 rpm, dropping the tablets at 
distance of 6 inches in each revolution, and then it was operated for 
4 min. This test was used to determine the effect of shock and 
abrasion in a plastic chamber with revolution. The tablets re-
weighed after removal of dusted fines and the percentage friability 
was calculated using the following formula. 
% Frability =  IW − FW
IW
∗ 100------- (1) 
Where IW: Initial weight; FW: Final weight 
Drug content uniformity 
10 tablets from each formulation have been selected randomly and 
crushed into a fine powder. The quantity of powder which equivalent to 
10 mg of Glipizide was taken and transferred to 100 ml volumetric flask 
and dissolved in 0.1NHCl (pH1.2) solution. Followed by measured the 
absorbance at 270 nm (λmax
The In vitro buoyancy test 
) using UV spectrophotometer (PG 
Instruments Limited, United Kingdom). The drug content in each 
formulation was calculated by using a standard calibration curve [31]. 
This study was performed in triplicate and the average % drug content 
in each formulation was reported as mean±SD. 
This study can be performed by using USP Tablet disintegration test 
apparatus II containing 900 ml of 0.1N HCl (pH 1.2) medium. By 
using this study, Floating lag time, (FLT) (time required for the 
tablet to reach the surface of the medium from the bottom) and 
floating duration or buoyancy (tablet which persistently floats in 
medium) can be calculated [32]. 
The Swelling index study (SI) 
The SI was performed by selecting 6 tablets from each formulation 
randomly and was weighed (W 0) separately and kept individually 
in a glass beaker containing 200 ml of 0.1N HCl and incubated at 
37 °C±1 °C. Then swollen floating tablets taken from the beaker and 
the excess surface liquid was removed and weighed for every 1h 
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time interval (Wt
SI = Wt − Wo
Wo
∗ 100 ------- (2) 
). The swelling index (SI) was calculated by using 
the following formula [35]. 
Where Wt is the weight of tablet at time t, W0
In vitro drug release studies  
 is the initial weight of the 
tablet 
The in vitro drug release study of Glipizide loaded floating tablets 
performed by using USP Type II instrument (Paddle Type). The 500 ml 
of 0.1N HCl dissolution media was maintained at 37±0.5 °C at 50 rpm for 
12h. A 5 ml aliquot sample was withdrawn from the dissolution test 
apparatus at various time intervals and the same volume of media was 
substituted with a fresh dissolution medium. The samples have been 
filtered through a 0.45 µm membrane filter and suitably diluted. The 
absorbance of these solutions was measured at λmax 
Kinetic analysis of release data 
270 nm by using a 
spectrophotometer [24] and this was performed in triplicate.  
The kinetic analysis of drug release data has been subjected to various 
kinetic models like first-order kinetics, Zero-order kinetics, Higuchi 
and Korsmeyer-Peppas models using DDSolver an add-in-program for 
Microsoft excel sheet. The correlation co-efficient (R2
In vitro mucoadhesion study 
) has been 
subjected to determine the best fit of the drug release mechanism. 
The in vitro mucoadhesion force was evaluated by the EZ-X500N 
Shimadzu texture analyzer (Singapore) using TRAPEZIUM X software. 
Fresh sheep gastric mucosa has been collected from a local 
slaughterhouse and used within 2h of slaughtering. The mucosal 
membrane was cleaned with distilled water and consequently with 
phosphate buffer pH 6.8 then fixed in between two plates followed by 
placed in a beaker. The tablet is carefully attached to a 10-mm cylindrical 
Jig with an adhesive tape. Then Jig moved down towards mucosa at a 
constant speed at 15 mm/S until a predetermined compressive force of 
0.5N withholding time 180 s and load cell 500 g was achieved. The Jig 
was subsequently moved up with a speed at 15 mm/S to a distance of 15 
mm. Followed by mucoadhesive strength and mucoadhesive 
detachment force was recorded. 3 tablets randomly selected from each 
formulation and employed on fresh mucosa [36, 37]. 
FTIR study 
The FTIR spectrum of the drug, CE, HPMC, and final formulations 
were recorded by using Bruker, Alpha FTIR Spectrophotometer for 
preparing sample pellets using KBr disk method. The scanning range 
was 400-4000 cm-1
DSC study 
. This study was used to determine the 
interaction and change of functional groups in between drug, 
powder extracts, polymer, and final formulation [38]. 
To confirm the further drug excipients interaction and thermal 
behavior property DSC was performed (Hitachi High-Tech Sciences-
Model DSC7020, USA). DSC was performed for drug, CE, HPMC, and 
F7. The 5 mg of the drug, HPMC, and final formulation were sealed in 
an empty preweighed aluminium pan, and scanned in the 
temperature range of 25–250 °C under an atmospheric nitrogen rate 
of 10 °C/min, followed by a cooling cycle back to a rate of 20 °C. A 
blank aluminium pan was used a reference [39]. 
XRD study 
XRD patterns of Glipizide, CE, HPMC, and final optimized 
formulation were analyzed by using the X-ray-diffractometer (P 
Analytical, The Netherlands). The powder sample has been sealed in 
rectangular aluminium cells, illuminated by using the Cu-Ka 
radiation (k = 1.54056 A) at 45 kV and 30 mA. The samples were 
scanned between diffraction angles of 6 to 80°. The scan step of 
0.008 was used and the d well time was 10s. A nickel filter was used 
to reduce the Kb contribution to the X-ray signal. The‘d’ spacing was 
computed according to Bragg’s law of diffraction [39]. 
RESULTS  
Formulation of glipizide floating tablets 
In the present exploration, mucoadhesive, floating, and sustained-
release tablets of Glipizide developed by using CE(F1), FG(F2),GG(3), 
HPMC K4M(F4) alone and in combination with CE+FG(F5), 
CE+GG(F6), CE+HPMC K4M(F7), FG+GG(F8) and FG+HPMC 
K4M(F9). Additionally, Citric acid® and Sodium bicarbonate® have 
been used as gas generating agents, whereas, Talc®, MCC®, 
Magnesium stearate®
 
 have been used as glidant, bulking agents, and 
lubricants respectively. The formulations have been demonstrated 
in table 1 [40].  
Table 2: Characterization of Glipizide loaded mucoadhesive sustained release floating tablets. 
Formulations Thickness (mm) %Weight Variation  Hardness (kg/cm2 %Friability ) 
F1 03.7±0.4 99±3.4 04.9±0.52 0.94±0.06 
F2 03.6±0.5 99±1.0 04.8±0.12 0.9±0.07 
F3 03.5±0.5 101±2.5 04.7±0.35 0.9±0.05 
F4 03.5±0.4 99±1.2 05.2±0.64 0.7±0.07 
F5 03.5±0.2 101±2.3 05.00±0.94 0.83±0.04 
F6 03.6±0.5 98±2.1 04.4±0.36 0.99±0.06 
F7 03.7±0.5 101±1.4  05.12±0.38 0.91±0.04 
F8 03.7±0.4 99±1.2 04.6±0.45 0.56±0.08 
F9 03.7±0.4 100±1.5 04.5±0.35 0.77±0.06 
The data is expressed as mean±SD, (Thickness, n=6), (Weight Variation, n=10), (Hardness=3), (Friability=20) 
 
Table 3: Drug content, Buoyancy log time, and Total floating time results of Glipizide loaded mucoadhesive sustained release floating tablets 
Formulations % drug content  Buoyancy lag time (s)  Total floating time (h)  
F1 100.52±0.50 30±05 1.0±0.20 
F2 99.48±0.50 34±06 1.0±0.30 
F3 102.07±1.5 564±54 16±0.50 
F4 101.56±2.0 41±09 20±0.85 
F5 102.07±2.50 42±07 1.0±0.37 
F6 100.00±1.30 220±36 20±1.20 
F7 101.04±0.55 353±35 20±0.65 
F8 101.04±1.25 330±12 18±1.50 
F9 101.04±0.14 291±12 18±0.50 
The data is expressed as mean±SD, (Percent drug content, n=10) (Buoyancy lag time (s), n=3), (Total floating time, n=3) 
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Physiochemical evaluation 
The developed formulations (F1-F9) were subjected to thickness, 
weight variation, hardness, friability, percent drug content, and the in 
vitro buoyancy studies, and the results expressed in table 2-3. The 
thicknesses of the tablets found to be 3 mm to 4 mm and the weight 
variation test results exhibited in the range of 98-101% and within 
acceptable limit. The hardness of the formulations F1-F3, F5-F8 was 
found to be in the range of 4-5 kg/cm2 (approx.), whereas 
formulations F4 and F9 exhibited in the range of 5-5.5 kg/cm2
The in vitro buoyancy test 
 
(approx.). Furthermore, the results of the friability test results found to 
be<1% for all formulations and were within the limits and acceptable. 
The percent drug content uniformity of formulations F1-F9 exhibited 
in the range of 99-102% (table 3). 
The results of the in vitro buoyancy study was expressed in table 3. 
Glipizide-loaded floating tablet formulations developed with FG, CE 
and CE+FG instantaneously floated to the surface of media and 
disappeared within 1h. It is indicated that the formulations F1-F2 
and F5 having a low density as compared to gastric fluid, although 
they may necessitate some additional matrix forming agents for 
maintaining prolonged floating duration in the stomach [41]. FLT of 
F3 and F4 found to be 564±54s and 60±12s respectively; it may be 
attributed to the strong hydrogel layer which was formed around 
the tablet layer. Whereas floating duration time was 16h for F3, it is 
indicated that the CO2
Swelling index study 
 was released from the gel matrix of the 
formulation. While the buoyant duration for formulation F4 was 20 
h. It might be attributed to the low viscosity of HPMC K4M. 
Therefore, the buoyancy duration time for F6 and F7 was 20 h. 
whereas; the FLT and buoyancy duration time for formulation F8 
and F9 was 630±12s, 291±12s and18 h respectively.  
The results of the swelling studies are expressed in table 4 and the 
F1 to F9 formulations have been shown the very good swelling 
properties. Furthermore, these results overlapped with the results 
of the in vitro buoyancy studies (floating duration). Also, the 
formulations from F6-F9 ensued in a very low viscous gel layer and 
encouraged the water to penetrate into the tablet layer, therefore SI 
was increased. Furthermore, formulation F3 exhibited moderate SI. 
It might be ascribed to the formation of a gel layer around the tablet 
core which was thick and it prevented the penetration of media into 
the tablet core [42]. 
 
Table 4: Swelling studies (% swelling index) of formulations from F1-F9 
Formulations 
Time (h) F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 181±11 134±08 165±09 134±08 189±09 198±10 166±08 172±08 180±07 
2 264±13 233±10 171±07 233±10 223±11 252±11 205±11 193±07 199±09 
3 313±16 241±13 199±08 241±13 268±11 292±14 250±11 225±11 236±10 
4 325±18 273±12 211±10 273±12 263±12 300±12 289±14 267±10 280±12 
6 326±12 294±14 230±11 294±14 270±10 332±10 301±13 290±10 320±18 
8 356±13 325±10 253±10 325±10 279±09 356±09 312±10 320±15 333±16 
10 366±19 354±10 275±9 354±10 289±08 366±12 324±12 332±13 345±11 
12 370±21 366±17 298±05 366±17 350±12 378±10 345±11 369±18 378±10 
The data is expressed as mean±SD(n=3) 
 
 
Fig. 1: The in vitro drug release profile of Glipizide loaded mucoadhesive sustained release floating tablets; 1a: Formulations from F1-F2, 
and F5; 1b. Formulations from F3-F4 and F6; 1c. F7-F9, The data is expressed as mean±SD, n=3 
 
In vitro drug release studies 
Glipizide-loaded floating tablets prepared with CE and FG and in a 
combination of CE+FG (F1-F2 and F5) demonstrated that 100% drug 
release in the period of 4 h (fig. 1a). The formulations developed 
with GG and HPMCK4M have confirmed that the prolonged floating 
duration along with drug release up to 12 h (F3-F4) (fig. 1b). It 
might be ascribed to the hydrophilic nature of GG, and HPMCK4M 
furthermore it could form a protective gel layer around the tablet 
core, thus arrests the drug release. The formulations developed with 
a combination of GG+CE (F6) (fig. 1b), HPMC K4M+CE (F7), GG+FG 
(F8), and HPMC K4M+FG (F9) (fig. 1c) exhibited drug release during 
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12h. It is stated that GG and HPMCK4M could act as a drug release 
retardant in said formulations. 
Kinetic analysis of release data 
The results of the drug release mechanism, correlation coefficient (R2
  
) 
and “n” was reported in table 5. The formulations from F1-F6 and F8 
exhibited first-order release kinetics; whereas the formulations F7 and 
F9 have exhibited Higuchi’s-model. Moreover, all the formulations 
subjected to the Peppas model, where the R value revealed, 
formulations were best fitted in the dissolution profile. The geometry 
of tablet is n =0.5 means Fickian diffusion, whereas 0.5<n<1.0 Non-
Fickian diffusion and n = 1.0 Case II diffusion [43, 44]. 
Table 5: Drug release kinetics data of Glipizide loaded mucoadhesive sustained release floating tablets 
R  2 
1 2 3 4 5 6 7 8 
F1 0.9010 0.7412 0.8417 0.9614 0.5697 2 Diffusion and swelling controlled, Anomalous diffusion or non fickian-diffusion 
F2 0.9120 0.7120 0.8315 0.9844 0.5789 2 Diffusion and swelling controlled, Anomalous diffusion or non fickian-diffusion 
F3 0.9545 0.9046 0.8245 0.9691 0.314 2 Diffusion and Quasi-fickian 
F4 0.8854 0.7411 0.8240 0.9471 0.558 2 Diffusion and swelling controlled, Anomalous diffusion or non fickian-diffusion 
F5 0.9501 0.98 0.9648 0.9616 0.565 2 Diffusion and swelling controlled, Anomalous diffusion or non fickian-diffusion 
F6 0.9477 0.9808 0.9535 0.9301 0.674 2 Diffusion and swelling controlled, Anomalous diffusion or non fickian-diffusion 
F7 0.9121 0.9795 0.9808 0.9759 0.552 4 Diffusion and swelling controlled, Anomalous diffusion or non fickian-diffusion 
F8 0.8322 0.9116 0.9558 0.9752 0.702 2 Diffusion and swelling controlled, Anomalous diffusion or non fickian-diffusion 
F9 0.6391 0.7791 0.832 0.8336 0.383 4 Diffusion and Quasi-fickian 
1. Formulation code; 2. First- order; 3. Zero-order.4. Higuchi’s; 5. Korsmeyer-Peppas; 6. nvalue; 7. Drug release model; 8. Mechanism and indication 
of drug release 
 
In vitro bioadhesion measurement 
The in vitro bioadhesiveness test involves the characterization of the 
bioadhesiveness property of polymers that can adhere to the 
mucosal layer of the gastrointestinal tract. In this process, 
bioadhesion could be formed by the electrostatic interaction-
bonding between the polymer and mucous layer [45]. Usually, 
floating tablets could be buoyant in gastric fluid when the stomach is 
full of meal; however, the buoyancy of the tablet gets disturbed when 
the stomach get emptied and moves from the pyloric sphincter to 
the small intestine [45]. Hence, the buoyancy capability of floating 
tablets in the stomach restricted to only 3–4h. Although, bioadhesive 
tablets can be attached to the gastric mucosal wall at feed state and 
semi-liquid substances could be agitating under the effect of 
peristaltic movement [46]. The results of the in vitro 
bioadhesiveness strength (J) found to be 06.610±0.95, 10.034±0.13, 
06.84±1.02, and 07.58±0.87 respectively for F6-F7. Whereas, the 
results of the bioadhesive detachment force (N/m2
FTIR study 
) found to be 
0.0648±0.0092, 0.0984±0.210, 0.0588±0.0872, and 0.0943±0.763 
for F6-F9 respectively. 
FTIR spectrum of drug and formulation (F7) did not show the major 
changes in the functional groups. It is indicating that the absence of 
drug and excipient interactions (fig. 2). Furthermore, the FTIR 
spectrum of formulations (F7) exhibited the presence of carboxyl 
groups and these groups can be the good binding site for the ions. 
Ghasemlou et al. 2011, reported that carboxyl groups could react 
with water and form an appropriate gel [43]. Moreover act as good 
bio adhesiveness agents by forming hydrogen bond between 
hydroxyl and carboxyl groups [43]. 
 
 
Fig. 2: FTIR spectrum of glipizide, CE, HPMC, and F7 
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DSC study  
DSC thermo grams of Glipizide, CE, HPMC, and F7 have been illustrated 
in fig. 3. The sharp endothermic peak of Glipizide observed at 217.5 °C. 
Where; the endothermic peak of CE and HPMC shown at 85.2 °C and 
58.2 °C respectively. The formulation (F7) illustrated an endothermic 
peak at 53.4 °C (broad), 77.0 °C (broad) 138.5 °C (broad), 160.0 °C 
(sharp) and they may be melting transition peaks of Sodium 
bicarbonate and Citric acid. Essa et al. 2015 stated that the related type 
peaks of bicarbonate and citric acid may not affect the physical state of 
the drug-loaded floating tablets [47]. Conversely, the sharp 
endothermic peak of Glipizide, CE, and HPMC disappeared in F7. 
 
 
Fig. 3: DSC thermograms of Glipizide, CE, HPMC, and F7 
 
 
Fig. 4: X-ray diffraction patterns of Glipizide, CE, HPMC, and F7 
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XRD study 
XRD analysis patterns of the Glipizide, CE, HPMC, and F7 has been 
illustrated in fig. 4. Glipizide exhibited various sharp peaks; it is 
signifying the crystalline nature of Glipizide; subsequently 
formulations F7 have revealed straight line and absence of 
characteristic peaks indicates. Nevertheless, formulation F7 has 
exhibited lots of very sharp characteristic peaks. This may be owing 
to the molecular transformation of polymers for the duration of 
compression, or sodium bicarbonate might be progressively 
converted into anhydrous sodium bicarbonate with increased 
temperature [45]. 
DISCUSSION 
The main objective of the present study was to develop a sustained 
release, mucoadhesive, and floating tablets of Glipizide for exploring 
CE, and FG as the potential buoyancy enhancing agents, and 
mucoadhesive agents. The swellable, immediately float, fast gastric 
emptying, long reside in the stomach, and sustained-release tablets 
of Glipizide was successfully developed by direct compression 
technique [40]. Results of the thickness showed that the tablets 
maintained uniform dimensions during manufacturing [15]. The 
weight variation test results found to be acceptable limits. As per the 
IP specifications for tablets more than 80 mg and less than 250 
mg,±7.5% is acceptable. These differences may be attributed to the 
deviation in particle size of powders [48]. The results of the 
hardness test revealed that the tablets having sufficient crush 
strength during transportation. Results of the friability study 
demonstrating that the developed formulations could withstand the 
mechanical shock during transportation [49]. The results of drug 
content indicative of the powder mixtures employed were free-
flowing, subsequently die cavity was uniformly filled during 
compression; hence uniform weight tablets obtained. The FLT and 
buoyancy duration time is the most important parameters for the 
development of successful GRDDS. The faster onset of action and 
faster duration of the floating tablet can prevent the movement of 
dosage form from the stomach to intestine and gives the local drug 
absorption [32, 50-51]. Therefore, buoyancy duration time for F6 
and F7 formulations was found to be 20 h; it might be ascribed to 
the synergistic property like swelling and buoyancy behavior of 
CE-GG (F6) and CE-HPMC K4M(F7) (52). Therefore F8 and F9 
discovered buoyancy duration time was 18 h. It may be attributed 
to the acceptable swelling property and hydrophilic nature of FG 
[53, 54]. 
The swelling properties of a tablet are the important parameter to 
retain the tablet in the pyloric sphincter. To achieve the goal of 
prolonged gastric retention, the tablets can swell more than 2 cm in 
size to prevent the passage of tablets through the pyloric sphincter 
[55]. Glipizide-loaded floating tablets made up of the matrix-forming 
agents; they might form a layer of gel around the tablet core, when 
they come in contact with the fluid. Due to the viscous gel layer of 
the tablet, the liquid medium incapable to come in contact with the 
tablet core and reduces the diffusion process, followed by drug 
release from a tablet may be decreased. The viscous gel layer of the 
tablet al. so affects the floating duration and swelling properties of a 
tablet [47]. The results of SI study revealed that tablets which have 
long buoyant duration time and shortest lag time caused low SI; 
subsequently, tablets with the shortest floating lag time and 
prolonged floating duration exhibited moderately high SI. From the 
results of the in vitro drug dissolution study data, it was confirmed 
that in combination of CE and FG with GG and HPMC K4M (F6-F9) 
has revealed the sustained release characteristics. Finally, it was an 
unambiguous that the natural macromolecules can be prominently 
potential for the development of a floating sustained release drug 
delivery system. The various mathematical models are available, 
among that Higuchi square root model is major one used to fit the 
kinetics of drug release from the tablets [56]. The formulation from 
F1-F6 and F8 showed Non-Fickian or anomalous diffusion 
illustrations due to the relaxation of the polymeric groups, and 
affects the drug releases. These hydrophilic glassy polymers when 
placed in media they may be swelling and show anomalous-diffusion 
[43, 44]. The hydrophilic glassy polymers swell in contact with 
water and become rubbery, then show anomalous-diffusion as a 
result of the rearrangement of macromolecular chains, whereas 
formulation F4 and F9 have been exhibited the Quassi-diffusion 
mechanism. Though, F7 revealed Anomalous diffusion or non 
fickian-diffusion. The formulation containing both GG and FG (F8) 
demonstrated higher bioadhesiveness strength than other 
formulations. It could be owing to the high molecular weight and 
strong hydrogen bond-forming groups between GG and FG [46]. The 
formulation F7 unveiled very high In vitro bioadhesiveness strength 
and detachment bioadhesive force as compared to other 
formulations. F7 revealed higher adhesion and adhesive force as 
compared to F6, F8, and F9. It might be a combination of CE and 
HPMC exhibited mucin interaction strongly. Typically, good wetting and 
swelling properties should correlate to good mucoadhesion, however 
only up to a certain point; polymer swelling behavior is essential for the 
exposure of the bioadhesive sites for the formation of strong hydrogen 
bonding and important character for uniform and sustained release of 
the drug and effective mucoadhesion [36, 37]. Therefore, based on the 
results of the In vitro buoyancy, in vitro drug release, in vitro 
bioadhesive studies and cost-effectiveness of CE compared to FG; F7 has 
been selected as the final formulation. FTIR data demonstrated that CE 
could be a good bioadhesiveness agent by forming a hydrogen bond 
between hydroxyl and carboxyl groups. DSC study results exhibited that 
the developed formulation was converted into amorphous form and 
absence of drug excipient interactions [47]. The XRD of formulations F7 
discovered the straight line and the absence of characteristic peaks 
indicates the amorphous nature. 
CONCLUSION 
The promising, novel optimized, swellable, mucoadhesive and 
sustained release, buoyant tablets of Glipizide successfully 
developed by using CE, FG, GG and HPMC K4M, and in combination 
of GG+CE (F6), CE+HPMC K4M(F7), GG+FG (F8), and HPMCK4M+FG 
(F9). The thickness, weight variation, hardness, friability, and drug 
content uniformity evaluation results found satisfactory. The in vitro 
buoyancy study results revealed the prolonged buoyant duration 
(12-18 h). The results of the SI studies for formulations F1 to F9 
have been shown the very good swelling properties. Thus, SI study 
results overlapped with results of the In vitro buoyancy studies. The 
In vitro drug release studies of formulations F1-F2, and F5 have 
revealed 100% drug release for a period of 4 h, although; F6-F9 
exhibited 100% drug release in the period of12 h. The formulations 
from F1-F6 and F8 exhibited in first-order release kinetics; whereas; 
the formulations F7 and F9 have been exhibited in Higuchi’s model. 
Among the various mathematical models; Higuchi model is the best 
fit model used in the kinetics of drug release. Moreover; In vitro 
mucoadhesive study results confirmed the good adhesive to GI 
mucosa and swelling of the tablet to prevent the movement of 
tablets from the stomach to intestine through the pyloric sphincter. 
FTIR and DSC study revealed the absence of drug excipient 
interactions, and XRD study exhibited the final formulation (F7) is 
amorphous. Therefore, the natural macromolecules (CE) may be 
potential, effective, safe carriers for improving buoyancy and novel 
hydrocolloids for the development of mucoadhesive and sustained 
release floating tablets of Glipizide. However, the results of the F7 
and F9 formulations were revealed mostly comparable in all 
evaluation data. But, CE could be cheap as compared to FG. Hence, 
CE might be the best potential natural macromolecule for the 
replacement of synthetic polymers. 
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